Scienture Holdings, Inc. (Nasdaq: SCNX) has entered into a securities purchase agreement with institutional investors to purchase 3,225,000 shares of common stock at an offering price of $1.20 per share.
The gross proceeds for the offering are expected to be approximately $3.9 million before deducting placement agent fees and other offering expenses.
The offering is expected to close on August 15, 2025, subject to customary closing conditions.
Offering Details
3,225,000 shares of common stock at $1.20 per share with expected gross proceeds of $3.9 million.
Placement Agent
Maxim Group LLC is acting as the sole placement agent in connection with the offering.
Registration Statement
The offering is made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-289198) declared effective on August 8, 2025.
- Scienture Holdings, Inc. aims to raise funds to support its pharmaceutical operating companies focused on developing novel specialty products.
- The successful completion of the offering demonstrates investor confidence in Scienture's market strategy and potential growth opportunities.
The securities purchase agreement marks a significant milestone for Scienture Holdings, Inc. in its pursuit of enhancing value for patients, physicians, and caregivers through innovative pharmaceutical products.